Navigation Links
Covington Advises Omthera Pharmaceuticals on Merger with AstraZeneca
Date:5/28/2013

NEW YORK, May 28, 2013 /PRNewswire/ -- Omthera Pharmaceuticals and AstraZeneca announced today that the companies entered into a merger agreement under which AstraZeneca will acquire all of the outstanding stock of Omthera for an upfront payment of $12.70 in cash per share, approximately $323 million aggregate value ($260 million after subtracting cash), plus a contingent value right for up to $4.70 per share, equaling approximately $120 million and for a total value of up to $443 million. Covington & Burling LLP advised Omthera on the transaction.

Omthera is an emerging specialty pharmaceutical company led by a team of experts with exceptional experience in developing new therapies for lipid disorders. Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease. AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.

The Covington team was led by corporate partner Scott Smith and corporate associate Matthew Fox, with the assistance of associates Patrick Manchester, Peter Kim and Aisha Granville.  Also advising on the transaction were partner Jim Snipes (life sciences commercial), partner Mike Lefever and associate Erik Durbin (securities), partner Seth Safra and counsel Kendra Roberson (benefits), partner Mike Labson and associates Afia Asamoah and Noellyn Davies (food & drug regulatory), partner James O'Connell and associate James Burke (antitrust), and partner Rob Heller and associate Sarah Burnham (tax).

Covington & Burling LLP, an international law firm, provides corporate, litigation, and regulatory expertise to enable clients to achieve their goals.  Founded in 1919, the firm has more than 800 lawyers and offices in Beijing, Brussels, London, New York, San Diego, San Francisco, Seoul, Shanghai, Silicon Valley, and Washington, DC.

Contact: An Pham
+1.202.662.6575
apham@cov.com


'/>"/>
SOURCE Covington & Burling LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises
2. Addressing Hearing Loss Proves Win-Win for Both Employer and Employee, BHI Advises During National Employee Wellness Month
3. Underage Kids Get Hydrocodone Drugs Easily from Family & Friends, Advises New York Center for Living
4. Intrepid Investment Bankers LLC Advises A-Med Health Care in the Sale of its Specialty Pharmacy Assets to Modern HC Pharmacy, Inc., a portfolio company of Altamont Capital Partners
5. Apex BioStrategists Advises On Flow Cytometry Sale To Coulter
6. Intrepid Investment Bankers LLC Advises Newport Medical Instruments, Inc. in its Sale to Covidien plc
7. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
8. Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
9. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
10. Omthera Pharmaceuticals Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... Company, Inc. (NYSE: LCI ) today announced ... against its existing revolving credit facility. ... payment we made earlier this year in January, will ... expense, at current rates" said Arthur Bedrosian , ... and we continue to generate strong cash flows, which ...
(Date:3/30/2017)... Research and Markets has announced the addition of the ... Type (Hemodialysis, Peritoneal Dialysis), By Product (Device, Consumables, Services), By ... report to their offering. ... The global hemodialysis and peritoneal ... 2025. Home-based dialysis treatment is anticipated ...
(Date:3/29/2017)... March 29, 2017  Bodycad announced today that ... (FDA) 510(k) clearance for its Bodycad Unicompartmental Knee ... personalized orthopaedic restoration. Bodycad is the first Canadian ... reconstruction implant system. Bodycad,s revolutionary ... restoration of the patient,s unique anatomical features and ...
Breaking Medicine Technology:
(Date:3/29/2017)... , ... March 29, 2017 , ... During the last ... provide free screening colonoscopies to eligible individuals in the local community. , Colon ... but regular screenings can detect colon cancer while it is small, confined and easier ...
(Date:3/29/2017)... , ... March 29, 2017 , ... Full Contact K9, ... of Pet Protect Law that assists dog owners in creating legally-enforceable pet ... owners in taking the natural next step to protect their new companion. Says Evan ...
(Date:3/29/2017)... Petersburg, FL (PRWEB) , ... March 30, 2017 , ... ... called the "Spice of Life" or "Wonder Spice", it has been used for thousands ... use in the East," says Heshelow, author of " Turmeric: How to Use it ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Wall Centre Dental ... new patients from Burnaby, BC. Patients in need of experienced orthodontics, laser dentistry, ... see the esteemed team at Wall Centre Dental. Drs. Parviz Roshan, Siamak Tehrani, ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... as it continues developing an ANSI-approved, consensus-based American National Standard for Good ... to publish the first ANSI-approved GMP standard for dietary supplements this spring, ...
Breaking Medicine News(10 mins):